Heatwurx (PCSA) Projected to Post Earnings on Thursday

Heatwurx (NASDAQ:PCSA) is projected to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($1.50) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Heatwurx Stock Performance

Shares of NASDAQ:PCSA opened at $3.16 on Wednesday. Heatwurx has a 1-year low of $1.76 and a 1-year high of $19.64. The company has a 50 day moving average price of $2.76 and a 200 day moving average price of $5.03. The stock has a market capitalization of $7.17 million, a price-to-earnings ratio of -0.09 and a beta of 1.05.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PCSA. Wall Street Zen lowered shares of Heatwurx from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.